Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Lung Neoplasms 3Neoplasm Metastasis 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Gallbladder Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × bintrafusp alfa protein, human × Clear all
NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

EMD Serono

Phase 2 Completed
159 enrolled 23 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04727541 2022-05-23

NEOBIL

AIO-Studien-gGmbH

Phase 2 Terminated
3 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡